Navigation Links
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Date:9/8/2008

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it received a milestone payment for an undisclosed amount from its licensing partner, Pfizer Inc. (NYSE: PFE). This payment is a result of the submission of an Investigational New Drug (IND) application by Pfizer for the clinical development of an antibody generated by Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

"We are pleased with the progress that Pfizer has made in advancing this antibody, generated using our UltiMAb(R) technology, towards the clinic," said Howard H. Pien, President and CEO of Medarex. "The continued development progress by Pfizer and our other partners reinforces the potential of products generated using our UltiMAb(R) antibody technology to treat life-threatening diseases."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
2. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
5. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
6. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Medarex Announces Ipilimumab Program Continues to Move Forward
9. Medarex to Receive Milestone Payment from Amgen
10. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
11. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 19 Celsion Corporation (Nasdaq: CLSN ... ThermoDox® High Intensity Focused Ultrasound (HIFU) development program ... MR-guided Focused Ultrasound 2010 2nd International Symposium.  The ... as the rationale and support for future clinical ...
... Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi ... reduce significantly deleterious side effects triggered by conventional ... operations. The company is currently developing a novel ... on its asymmetric shorter-duplex siRNA (asiRNA) technology, originally ...
Cached Medicine Technology:Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium 2Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium 3BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors 2BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors 3
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
... Rehabilitation Research and Development (JRRD) mainly analyses articles related ... sexuality, chronic pain and prosthetics research. ,Under ... pain associated with spinal cord injury the author of ... cord injury) reported chronic pain. He inquired about their ...
... are said to account for a large portion of ... to assess// this assumption in the Arab world. ... WHO World Mental Health (WMH) Survey Initiative, a nationally ... in Lebanon between September, 2002, and September, 2003, through ...
... School of Veterinary Medicine have established a national ... to humans and animals using medical records of ... Professor of Epidemiology. Larry Glickman of the School ... Pet Hospital, a nationwide chain of veterinary hospitals ...
... Pete Burns, following complaints of "sleep deprivation and exhaustion", has ... ,Burns, who is 46, had been residing at ... expensive pounds 450-a-night. There has been gossip doing the rounds ... the star out of his room for not paying his ...
... study by the New England Research Institutes in collaboration with ... or too little// are at a greater risk of developing ... based on studies done on over 1709 men, in the ... a period of 15 yrs. ,According to the ...
... A novel study conducted by Columbia University Medical ... for use in osteoarthritis, could be effective// in ... Until now, drug treatment with Cox-2 inhibitors or ... patients with chronic shoulder pain. ,Approximately ...
Cached Medicine News:Health News:JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics 2Health News:JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics 3Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2Health News:Pets As Disease Watchdogs 2Health News:Sodium Hyaluronate Shows Promise In Treatment Of Shoulder Pain 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: